Ellume have a habit of not mentioning Anteo , a 5 year supply agreement is in place , Ellume own the device , Anteo make it work , no doubt Anteo are involved.
The undisclosed commercial arrangement shall see Ellume utilise Anteo’s proprietary technology across its suite of pipeline products. The first to be launched influenza product will be released to the professional market in 2017. Other pipeline products include Respiratory Syncytial Virus,
ADO Price at posting:
1.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)